1. SciScore for 10.1101/2021.10.11.21263897: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: All sites received approval from the authorized institutional review board.
    Consent: All participants (or legally authorized representatives) provided informed consent.
    Sex as a biological variablenot detected.
    RandomizationStudy Design and participants: The COV-BARRIER addendum trial in persons with baseline IMV/ECMO was a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 3 trial which were enrolled from 18 centres in four countries (Argentina, Brazil, Mexico, United States).
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    No key resources detected.


    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Despite the large effect size seen here in this well conducted, global, randomised, placebo-controlled trial, limitations exist. Limitations include the small sample size (which precludes any firm conclusions regarding other clinical outcomes such as resource utilisation or length of stay), and incomplete control of the SOC, specifically glucocorticoids. In addition, the intensity of these participants hyperinflammatory state may warrant longer durations of immunomodulation that were not part of our study design. In summary, treatment with baricitinib plus SOC (including use of corticosteroids) in critically ill COVID-19 patients already receiving IMV or ECMO at enrolment resulted in a HR of 0·56, which corresponds to a 44% relative reduction in mortality at 60 days. These results are consistent with the reduction in mortality observed in the less severely ill hospitalised patients in the primary COV-BARRIER study population and further support the use of baricitinib in hospitalised adults with COVID-19. Baricitinib used to treat critically ill persons with COVID-19 represents a novel option to reduce mortality even if the disease process has progressed to the point of already receiving steroids, mechanical ventilation, and ECMO.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04421027CompletedA Study of Baricitinib (LY3009104) in Participants With COVI…


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a protocol registration statement.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    Read the original source
    Was this evaluation helpful?